Who Paid My Doc
Carlos Mena-Hurtado
Cardiovascular Disease New Haven, CT Medical Doctor
NPI 1205800273 CMS profile 54727
333 Cedar St, Yale Physicians Building, New Haven, CT 06510
General payments
$460,161
Research payments
$18,320
Ownership & investment interest
$0
Research they led as principal investigator
$205,000
Through program year 2025, Carlos Mena-Hurtado of New Haven, CT is reported in the CMS Open Payments database as having received $460,161 across 283 general payments and $18,320 in research payments paid to them. Separately, studies naming them as principal investigator received $205,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $56,739 | 9 | |
| 2024 | General | $67,294 | 10 | |
| 2023 | General | $15,564 | 9 | |
| 2022 | General | $26,668 | 16 | |
| 2021 | General | $37,737 | 23 | |
| 2020 | General | $28,615 | 32 | |
| 2020 | Research | $18,320 | 5 | |
| 2019 | General | $227,543 | 184 |
Beside peers
- Carlos Mena-Hurtado
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Carlos Mena-Hurtado were reported at $56,739. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Carlos Mena-Hurtado | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $227,543 | $450 | $127–$1,392 | $163 |
| 2020 | $28,615 | $242 | $77–$751 | $114 |
| 2021 | $37,737 | $335 | $101–$1,037 | $132 |
| 2022 | $26,668 | $395 | $121–$1,211 | $149 |
| 2023 | $15,564 | $443 | $136–$1,283 | $160 |
| 2024 | $67,294 | $450 | $136–$1,323 | $164 |
| 2025 | $56,739 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
537
Drug cost
$70,308
Branded share of claims
35.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 19 | $23,600 | |
| Eliquis Apixaban | Brand | 23 | $20,972 | |
| Brilinta Ticagrelor | Brand | 13 | $12,862 | |
| Praluent Pen Alirocumab | Brand | 15 | $8,276 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 112 | $1,303 | |
| Cilostazol | Generic | 16 | $577 | |
| Atorvastatin Calcium | Generic | 56 | $550 | |
| Rosuvastatin Calcium | Generic | 40 | $497 | |
| Ezetimibe | Generic | 18 | $338 | |
| Carvedilol | Generic | 15 | $202 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 71 billing codesPaid by Medicare
$188,711
Medicare patients
571
Services billed
2,502
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 71% | |
| Arthritis | 54% | |
| Diabetes | 47% | |
| Heart failure | 40% | |
| Chronic kidney disease | 36% | |
| Atrial fibrillation | 31% | |
| COPD | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
288 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Connecticut
Nihar Desai
Cardiovascular Disease · New Haven, CT
Brett Nowlan
Cardiovascular Disease · Bloomfield, CT
Jeffery Testani
Cardiovascular Disease · New Haven, CT
Stephanie Saucier
Cardiovascular Disease · Hartford, CT
John Forrest
Cardiovascular Disease · New Haven, CT
Henry Ward
Cardiovascular Disease · New Haven, CT
Related records
Cardiovascular Disease in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.